Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.59 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.53 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.53 |
| ▸ | CALCR | P30988 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233254 | 0.98 | OPRD1 (0.61) | OPRD1OPRM1NMUR2NMUR1CALCR | |
| SCHEMBL30753761 | 0.97 | OPRD1 (0.61) | OPRD1OPRM1NMUR2NMUR1CALCR | |
| SCHEMBL30233411 | 0.91 | CALCR (0.63) | OPRD1OPRM1CALCR | |
| SCHEMBL30788361 | 0.91 | NMUR2 (0.56) | OPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL30753759 | 0.90 | NMUR2 (0.62) | OPRD1OPRM1NMUR2NMUR1CALCR | |
| SCHEMBL30233484 | 0.90 | NPY1R (0.57) | OPRD1OPRM1NMUR2NMUR1NTSR1 | |
| SCHEMBL30163248 | 0.89 | OPRM1 (0.55) | OPRD1OPRM1CALCR | |
| SCHEMBL30788354 | 0.89 | TFPI (0.55) | OPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL14549930 | 0.88 | OPRM1 (0.55) | OPRD1OPRM1CALCR | |
| SCHEMBL15130591 | 0.88 | OPRM1 (0.55) | OPRD1OPRM1CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| CN-115702161-A | Peptide compositions and methods for inhibiting nicotinic acetylcholine receptor activity | 格罗制药公司 | 2023-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | OPRD1 2819/4885OPRM1 2825/4885NMUR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.